Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  cediranib maleate
Find trials that include:  Any drugs shown
Results 1-6 of 6 for your search:
Start Over
Olaparib or Cediranib Maleate and Olaparib Compared with Standard Platinum-Based Chemotherapy in Treating Patients with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: Not specified
Trial IDs: NRG-GY004, NCI-2015-00606, NCT02446600
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Phase: Phase II, Phase I
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: S0905, NCI-2011-02015, CDR0000665415, SWOG-S0905, NCT01064648
Cediranib Maleate and Olaparib in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-293, NCI-2012-02938, DFCI IRB 09-293, NCI-2010-01329, NCI-2013-00578, NCT01115829, P8348_A26PAMDREVW01, 8348, NCT01116648
Cediranib Maleate in Treating Patients with Metastatic Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-C-0192, NCI-2013-01452, 090192, P09512, 8463, NCT00942877
Sunitinib Malate or Cediranib Maleate in Treating Patients with Metastatic Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 to 20
Trial IDs: 11-C-0200, NCI-2013-01496, 110200, P11836, P8875_A21PAMDREVW01, 8875, NCT01391962
Olaparib and Cediranib Maleate in Treating Patients with Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9825, NCI-2015-00051, NCT02345265
Start Over